温馨提示:优宁维所有产品和服务仅用于科学研究,不用于临床等诊断及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
| 反应性 | H |
| 灵敏度 | 内源性 |
| MW (kDa) | 40-50 |
| 来源/同种型 | 兔 IgG |
应用关键词:
- WB- 蛋白质印迹法
- IP-免疫沉淀法
- IHC-免疫组织化学法
- ChIP-染色质免疫沉淀法
- IF-免疫荧光法
- F-流式细胞术
- E-P-ELISA 肽
物种交叉反应性关键词:
- H-人
- M-小鼠
- R-大鼠
- Hm- 仓鼠
- Mk-猴
- Vir- 病毒
- Mi-水貂
- C-鸡
- Dm-黑腹果蝇
- X-爪蟾
- Z-斑马鱼
- B-牛
- DG-犬
- PG-猪
- Sc-酿酒酵母
- Ce-秀丽隐杆线虫
- Hr-马
- All-预期所有物种
产品使用信息
| 应用 | 稀释度 |
| 蛋白质印迹法 | 1:1000 |
| 免疫沉淀法 | 1:50 |
| IHC-Leica® Bond™ | 1:200 - 1:800 |
| 免疫组织化学(石蜡) | 1:100 - 1:400 |
| 流式细胞术 | 1:200 - 1:800 |
保存
保存在 10 mM sodium HEPES (pH 7.5)、150 mM NaCl、100 μg/ml BSA、50% 甘油和低于 0.02% 的中。-20℃ 保存。切勿分装抗体。
特异性/灵敏度
PD-L1 (E1L3N®) XP® Rabbit mAb 可识别内源水平的 PD-L1 总蛋白。
物种反应性:
人
来源/纯化
使用与人 PD-L1 蛋白中羧基末端周围的残基相对应的合成肽,对动物进行免疫接种来产生单克隆抗体。
背景
Programmed cell death protein 1 ligａnd 1 (PD-L1, B7-H1, CD274) is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses. The PD-L1 ligａnd binds to the PD-1 transmembrane receptor and inhibits T cell activation. PD-L1 was discovered after many B7 protein homologues were found, and it was later shown to be expressed in antigen-presenting cells, activated T cells, and tissues such as placenta, heart, and lung (1-3). PD-L1 is structurally similar to B7 family members in that it contains extracellular IgV and IgC domains and a short cytoplasmic region. Studies have shown that PD-L1 is expressed in cells of many tumor types including melanoma, ovarian, colon, lung, breast and renal cell carcinomas (4-6). PD-L1 expression in cancer cells is associated with tumor-infiltrating lymphocytes, which mediate PD-L1 expression through the release of interferon gamma (7). Other studies have implicated PD-L1 expression in viral infection-related cancers (8,9). - Dong, H. et al. (1999) Nat Med 5, 1365-9.
- Freeman, GJ et al. (2000) J Exp Med 192, 1027-34.
- Liang, SC et al. (2003) Eur J Immunol 33, 2706-16.
- Dong, H. et al. (2002) Nat Med 8, 793-800.
- Thompson, RH et al. (2006) Cancer Res 66, 3381-5.
- Pardoll, DM (2012) Nat Rev Cancer 12, 252-64.
- Taube, JM et al. (2012) Sci Transl Med 4, 127ra37.
- Lyford-Pike, S. et al. (2013) Cancer Res 73, 1733-41.
- Chen, BJ et al. (2013) Clin Cancer Res 19, 3462-73.
- Wimberly, H. et al. (2014) Cancer Immunol Res ,
